CLX

Business Profile & Competitive Position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry, operating as a multinational manufacturer and marketer of consumer and professional products. Its fiscal 2026 net sales reached $6.7 billion, generated by roughly 9,200 employees across approximately 25 countries and sold into about 95 markets. The consumer brand portfolio includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while the professional segment sells under Purell, CloroxPro, and Clorox Healthcare. That breadth gives Clorox shelf presence in cleaning, food, bags and wraps, charcoal, water filtration, and personal care, plus a growing business-to-business health and hygiene arm.

A net margin of 8.7% is respectable for a branded household-products business, but it is not elite, suggesting that private-label competition and retail pricing pressure are real constraints on pricing power. The reported ROE of -1,893.5% is not a profitability reading in the conventional sense; it signals that shareholders’ equity is deeply negative or near zero, often the result of cumulative share buybacks, accounting write-downs, and/or retained earnings erosion. Because of that, ROE is effectively unusable as a moat gauge here. The more useful signals are brand recognition, distribution scale, and the ability to command shelf space at major retailers.

Financial Posture

Clorox currently carries an $11.9 billion market capitalization and trades at a P/E of 20.4, which sits in a reasonable zone for a low-growth, dividend-oriented consumer staples name. The beta is 0.54, meaning the stock has historically moved about half as much as the broader market, consistent with the defensive characteristics investors usually associate with household products.

The negative equity implied by the extreme ROE figure means leverage and balance-sheet structure deserve extra scrutiny. A consumer staples company can operate with negative book equity for years if free cash flow is stable, but it also means the balance sheet is not conventionally fortified. Net margin of 8.7% provides some cover, yet fiscal 2026 saw organic sales and earnings declines, with diluted EPS down 26%, partly tied to macroeconomic headwinds and the timing of an ERP transition that had pulled some sales forward into fiscal 2025. That margin level, combined with the sales concentration discussed below, suggests Clorox is in a repair-and-stabilization phase rather than a high-growth expansion.

Strategic Priorities & Outlook

The company’s most recent 10-K outlines a strategy built around its IGNITE framework, which emphasizes four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Operationally, management is focused on completing and optimizing a new enterprise resource planning (ERP) system and a broader digital transformation aimed at generating long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

A second priority is portfolio optimization and health-and-hygiene expansion. The April 2026 completion of the GOJO Industries acquisition added Purell and expanded Clorox’s professional and institutional presence. Clorox is also investing in strong brands and strategic digital capabilities while streamlining the operating model to build a more resilient company and deliver consistent, profitable growth.

There are also portfolio-specific transitions to monitor. The Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, requiring Clorox to purchase P&G’s 20% interest; Glad retained core intellectual property licenses on a royalty-free basis. On the customer side, Walmart accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half of consolidated net sales. That scale creates distribution stability but also significant negotiating leverage for retailers and meaningful concentration risk in any contract or shelf-reset dispute.

Macro & Geopolitical Exposure

As a Household & Personal Products company, Clorox is exposed to the cost structure of raw materials such as resins, plastics, pulp-based liners, chemicals, and fragrances. Freight, fuel, and transportation costs also move directly through the income statement, while currency translation affects reported results across roughly 95 markets.

Consumer staples are generally recession-resistant, but they are not immune to trade-down behavior when households are under pressure. The industry also faces regulatory exposure around product safety, environmental claims, chemical formulations, and packaging sustainability. Tariffs or trade restrictions on imported inputs could pressure margins further, and any escalation in U.S.-China or North American trade policy could ripple through packaging and chemical supply chains. Interest-rate shifts matter indirectly: higher rates can dampen consumer discretionary spending broadly, while lower rates can support valuation multiples across the sector.

Recent Developments

Recent headlines have cast Clorox in an income-investor light. On August 26, 2026, YouTube carried a segment titled “3 Cheap Stocks Offering Attractive Income,” and on August 24, 2026, Fool.com asked “Should Passive Income Investors Buy Clorox Stock?” The same day, defenseworld.net reported that Barrow Hanley Mewhinney & Strauss LLC acquired 106,377 shares of The Clorox Company, while Bank of New York Mellon Corp made a new $123.15 million investment in the stock. Those institutional flows are factual capital-allocation events; they do not by themselves signal a buy thesis, but they do show that large asset managers were adding exposure around late August 2026.

Earnings Behavior & Post-Earnings Drift

Clorox has beaten the market’s real expectation in six of the last eight reported quarters, a 75% beat rate, with an average earnings surprise of 9.4%. The average 5-day price move following earnings across those quarters has been +1.67%, classified as an upward post-earnings drift.

But the recent quarter-by-quarter record shows wide dispersion beneath that average. The August 3, 2026 report delivered actual EPS of $1.66 against an estimate of $1.64, a modest 1.2% surprise, yet the stock jumped 6.52% the next day and 9.61% over the following five sessions. By contrast, the April 30, 2026 quarter beat by 5.8% ($1.64 actual vs. $1.55 estimate) and still sold off 9.67% the next day and 4.49% over the next five days. The February 3, 2026 report was a 2.8% miss ($1.39 vs. $1.43 estimate), yet the stock rose 2.43% the next day and 5.63% over five days. November 3, 2025 showed a 3.9% beat ($0.85 vs. $0.818) with a 1.17% next-day gain but a 4.08% five-day decline.

That pattern suggests the stock does not always reward beats or punish misses in a mechanical way; forward guidance, margin commentary, and the state of the ERP transition likely drive the post-earnage reaction more than the headline EPS number alone. The next scheduled report is November 3, 2026, after the close, with a consensus EPS estimate of $1.11.

For a deeper dive into the full institutional verdict on Clorox, including how sell-side analysts are modeling the November 2026 quarter and the ERP-driven margin trajectory, explore the comprehensive institutional research coverage available on the platform.